{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Rare+Cancer",
    "query": {
      "condition": "Rare Cancer"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 104,
    "total_pages": 11,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Rare+Cancer&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-07-21T16:32:48.533Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04931342",
      "title": "A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ovarian Cancer"
      ],
      "interventions": [
        {
          "name": "Ipatasertib",
          "type": "DRUG"
        },
        {
          "name": "Cobimetinib",
          "type": "DRUG"
        },
        {
          "name": "Trastuzumab Emtansine",
          "type": "DRUG"
        },
        {
          "name": "Atezolizumab",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Giredestrant",
          "type": "DRUG"
        },
        {
          "name": "Abemaciclib",
          "type": "DRUG"
        },
        {
          "name": "Inavolisib",
          "type": "DRUG"
        },
        {
          "name": "Palbociclib",
          "type": "DRUG"
        },
        {
          "name": "Letrozole",
          "type": "DRUG"
        },
        {
          "name": "Olaparib",
          "type": "DRUG"
        },
        {
          "name": "Luteinizing Hormone-Releasing Hormone (LHRH) Agonists",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 176,
      "start_date": "2021-10-07",
      "completion_date": "2028-05-30",
      "has_results": false,
      "last_update_posted_date": "2026-06-08",
      "last_synced_at": "2026-07-21T16:32:48.533Z",
      "location_count": 8,
      "location_summary": "San Francisco, California • St Louis, Missouri • Charlotte, North Carolina + 5 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Charlotte",
          "state": "North Carolina"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        },
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04931342"
    },
    {
      "nct_id": "NCT04482309",
      "title": "A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal Cancer",
        "Part 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorectal Cancer"
      ],
      "interventions": [
        {
          "name": "Trastuzumab deruxtecan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 477,
      "start_date": "2020-08-18",
      "completion_date": "2027-03-23",
      "has_results": false,
      "last_update_posted_date": "2026-07-10",
      "last_synced_at": "2026-07-21T16:32:48.533Z",
      "location_count": 12,
      "location_summary": "Duarte, California • Santa Rosa, California • Chicago, Illinois + 8 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Santa Rosa",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Muncie",
          "state": "Indiana"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04482309"
    },
    {
      "nct_id": "NCT05715281",
      "title": "Testing the Combination of Anti-cancer Drugs Atezolizumab and Tiragolumab in People With Advanced Stage Rare Cancers, RARE3 Trial",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Advanced Rare Malignant Solid Neoplasm",
        "Rare Malignant Solid Neoplasm",
        "Refractory Rare Malignant Solid Neoplasm"
      ],
      "interventions": [
        {
          "name": "Atezolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Biopsy Procedure",
          "type": "PROCEDURE"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Echocardiography Test",
          "type": "PROCEDURE"
        },
        {
          "name": "Tiragolumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2023-09-26",
      "completion_date": "2026-11-21",
      "has_results": false,
      "last_update_posted_date": "2025-11-25",
      "last_synced_at": "2026-07-21T16:32:48.533Z",
      "location_count": 3,
      "location_summary": "Bethesda, Maryland • Columbus, Ohio",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05715281"
    },
    {
      "nct_id": "NCT07229339",
      "title": "Zipalertinib With Carboplatin and Pemetrexed for the Treatment of Resectable, Stage II-IIIB, Non-Small Cell Lung Cancer",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lung Non-Squamous Non-Small Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Pemetrexed",
          "type": "DRUG"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Zipalertinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "Jonsson Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 16,
      "start_date": "2027-06-01",
      "completion_date": "2030-06-01",
      "has_results": false,
      "last_update_posted_date": "2026-02-05",
      "last_synced_at": "2026-07-21T16:32:48.533Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07229339"
    },
    {
      "nct_id": "NCT03264131",
      "title": "BV-CHEP Chemotherapy for Adult T-cell Leukemia or Lymphoma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lymphoma",
        "Adult T-Cell Leukemia/Lymphoma",
        "Lymphatic Diseases"
      ],
      "interventions": [
        {
          "name": "Brentuximab Vedotin",
          "type": "DRUG"
        },
        {
          "name": "CHEP",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "UNC Lineberger Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 16,
      "start_date": "2018-10-11",
      "completion_date": "2028-12-15",
      "has_results": true,
      "last_update_posted_date": "2025-02-10",
      "last_synced_at": "2026-07-21T16:32:48.533Z",
      "location_count": 4,
      "location_summary": "Hollywood, Florida • Boston, Massachusetts • Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Hollywood",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03264131"
    },
    {
      "nct_id": "NCT02285582",
      "title": "International Rare Histiocytic Disorders Registry (IRHDR)",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Rare Histiocytic Disorders (RHDs)",
        "Erdheim-Chester Disease (ECD)",
        "Rosai-Dorfman Disease (RDD)",
        "Xanthogranuloma Family (XG)",
        "Indeterminate Dendritic Cell Histiocytosis",
        "Malignant Histiocytic Neoplasm (MHN)",
        "ALK-positive Histiocytosis",
        "Mixed Histiocytosis (MXH)",
        "Multicentric Reticulohistiocytoma (MRH)",
        "Necrobiotic Xanthogranuloma (NX)"
      ],
      "interventions": [
        {
          "name": "Registry study",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "The Hospital for Sick Children",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 400,
      "start_date": "2014-10",
      "completion_date": "2028-09",
      "has_results": false,
      "last_update_posted_date": "2025-06-24",
      "last_synced_at": "2026-07-21T16:32:48.533Z",
      "location_count": 6,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • Madera, California + 3 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Madera",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02285582"
    },
    {
      "nct_id": "NCT02938793",
      "title": "Durvalumab in Combination With Tremelimumab in Subjects With Advanced Rare Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cancer",
        "Rare Disease"
      ],
      "interventions": [
        {
          "name": "Durvalumab",
          "type": "DRUG"
        },
        {
          "name": "Tremelimumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Prisma Health-Upstate",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 92,
      "start_date": "2016-12-01",
      "completion_date": "2025-09-17",
      "has_results": false,
      "last_update_posted_date": "2025-09-23",
      "last_synced_at": "2026-07-21T16:32:48.533Z",
      "location_count": 1,
      "location_summary": "Greenville, South Carolina",
      "locations": [
        {
          "city": "Greenville",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02938793"
    },
    {
      "nct_id": "NCT03251989",
      "title": "Rare CNS Tumors Outcomes &Risk",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "High Grade Meningioma",
        "Ependymoma",
        "Medulloblastoma",
        "PNET",
        "Primary CNS Sarcoma"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 326,
      "start_date": "2017-08-21",
      "completion_date": "2025-05-06",
      "has_results": false,
      "last_update_posted_date": "2026-07-10",
      "last_synced_at": "2026-07-21T16:32:48.533Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03251989"
    },
    {
      "nct_id": "NCT02978625",
      "title": "Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Anaplastic Large Cell Lymphoma, ALK-Negative",
        "Anaplastic Large Cell Lymphoma, ALK-Positive",
        "Apocrine Carcinoma",
        "Carcinoma Arising From Cylindroma",
        "Carcinoma Arising From Spiradenoma",
        "Digital Papillary Adenocarcinoma",
        "Endocrine Mucin-Producing Sweat Gland Carcinoma",
        "Extramammary Paget Disease",
        "Extraocular Sebaceous Carcinoma",
        "Hidradenocarcinoma",
        "Malignant Sweat Gland Neoplasm",
        "Merkel Cell Carcinoma",
        "Microcystic Adnexal Carcinoma",
        "NK-Cell Lymphoma, Unclassifiable",
        "Papillary Adenocarcinoma",
        "Porocarcinoma",
        "Primary Cutaneous Mucinous Carcinoma",
        "Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma",
        "Recurrent T-Cell Non-Hodgkin Lymphoma",
        "Refractory Anaplastic Large Cell Lymphoma",
        "Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma",
        "Refractory Merkel Cell Carcinoma",
        "Refractory Mycosis Fungoides",
        "Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma",
        "Refractory Skin Squamous Cell Carcinoma",
        "Refractory T-Cell Non-Hodgkin Lymphoma",
        "Sezary Syndrome",
        "Signet Ring Cell Adenocarcinoma",
        "Skin Adenoid Cystic Carcinoma",
        "Skin Adnexal Carcinoma",
        "Skin Basal Cell Carcinoma",
        "Skin Basosquamous Cell Carcinoma",
        "Skin Keratoacanthoma",
        "Skin Squamous Cell Carcinoma",
        "Squamoid Eccrine Ductal Carcinoma",
        "Squamous Cell Carcinoma of Unknown Primary",
        "Sweat Gland Carcinoma",
        "Trichilemmal Carcinoma",
        "Vulvar Squamous Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Biopsy Procedure",
          "type": "PROCEDURE"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Positron Emission Mammography",
          "type": "PROCEDURE"
        },
        {
          "name": "Talimogene Laherparepvec",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "OTHER",
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 68,
      "start_date": "2017-09-27",
      "completion_date": "2027-09-01",
      "has_results": false,
      "last_update_posted_date": "2026-05-13",
      "last_synced_at": "2026-07-21T16:32:48.533Z",
      "location_count": 36,
      "location_summary": "Los Angeles, California • Orange, California • Pasadena, California + 28 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Pasadena",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02978625"
    },
    {
      "nct_id": "NCT05910307",
      "title": "Synovial Sarcoma Registry / Biospecimen Repository",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Synovial Sarcoma"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Children's Hospital of Philadelphia",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 1000,
      "start_date": "2023-06-12",
      "completion_date": "2033-06",
      "has_results": false,
      "last_update_posted_date": "2026-06-09",
      "last_synced_at": "2026-07-21T16:32:48.533Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05910307"
    }
  ]
}